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Research Breast carcinoma cells re-express E-cadherin 
during mesenchymal to epithelial reverting 
transition
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Abstract
Background: Epithelial to mesenchymal transition (EMT), implicated as a mechanism for tumor dissemination, is 
marked by loss of E-cadherin, disruption of cell adhesion, and induction of cell motility and invasion. In most 
intraductal breast carcinomas E-cadherin is regulated epigenetically via methylation of the promoter. E-cadherin 
expression is therefore dynamic and open to modulation by the microenvironment. In addition, it has been observed 
that metastatic foci commonly appear more differentiated than the primary tumor, suggesting that cancer cells may 
further undergo a mesenchymal to epithelial reverting transition (MErT) in the secondary organ environment following 
the EMT that allows for escape.
Results: We first examined E-cadherin expression in primary breast tumors and their corresponding metastases to liver, 
lung and brain and discovered that 62% (10/16) of cases showed increased E-cadherin expression in the metastases 
compared to the primaries. These observations led to the question of whether the positive metastatic foci arose from 
expansion of E-cadherin-positive cells or from MErT of originally E-cadherin-negative disseminated cells. Thus, we 
aimed to determine whether it was possible for the mesenchymal-like MDA-MB-231 breast cancer cells to undergo an 
MErT through the re-expression of E-cadherin, either through exogenous introduction or induction by the 
microenvironment. Ectopic expression of full-length E-cadherin in MDA-MB-231 cells resulted in a morphological and 
functional reversion of the epithelial phenotype, with even just the cytosolic domain of E-cadherin yielding a partial 
phenotype. Introduction of MDA-MB-231 cells or primary explants into a secondary organ environment simulated by a 
hepatocyte coculture system induced E-cadherin re-expression through passive loss of methylation of the promoter. 
Furthermore, detection of E-cadherin-positive metastatic foci following the spontaneous metastasis of MDA-MB-231 
cells injected into the mammary fat pad of mice suggests that this re-expression is functional.
Conclusions: Our clinical observations and experimental data indicate that the secondary organ microenvironment 
can induce the re-expression of E-cadherin and consequently MErT. This phenotypic change is reflected in altered cell 
behavior and thus may be a critical step in cell survival at metastatic sites.
Introduction
Breast cancer is the most frequently diagnosed cancer in
women, and it is the second leading cause of cancer death
in women of all ages [1]. Intraductal carcinoma, which
originates from the epithelial cells lining the mammary
ducts, is the most common type of breast cancer. Metas-
tasis occurs via a series of sequential steps, during which
the cells acquire an amoeboid-like phenotype, become
motile, disseminate, and colonize distant sites of the
body, which in breast cancer are most commonly liver,
lung, bone, and brain. The stages of this transformation
are similar to the stages of the developmental process
known as epithelial to mesenchymal transition (EMT)
[2]. Much of the current literature supports the idea that
EMT is the key mechanism by which tumor cells gain
invasive and metastatic ability, as EMT enables separa-
tion of individual cells from the primary tumor mass as
well as promotes migration [3,4]. After undergoing EMT,
thereby enabling access to hematogenous or lymphatic
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routes of dissemination, tumor cells can extravasate into
secondary organs and establish micrometastases. We
h a v e  h y p o t h e s i z e d  t h a t  E M T  i s  r e v e r s i b l e  a n d  t h a t  a
reversion back towards the epithelial phenotype may
occur at the secondary metastatic site (MErT). A similar
reversion occurs in development when neural crest cells
undergo a transient EMT followed by a permanent MET
t o  g e n e r a t e  t i s s u e s  s u c h  as  ki d n ey  e p i t h e l i a  [ 5 ] .  A  f ew
studies have charted switches between EMT and MET
phenotypes throughout malignant progression such as in
colorectal cancer [6], bladder cancer [7], and ovarian can-
cer [8]. The phenotypic plasticity observed in these cases
is unlikely to be generated by the acquisition of perma-
nent genetic insults, suggesting that the microenviron-
ment is capable of inducing epigenetic changes.
Numerous extracellular signals such as growth factors
and stromal signals, and stressors such as hypoxia and
ROS have been implicated in the induction of EMT [9].
However, at the core of the transition between an epithe-
lial and a mesenchymal phenotype is the loss of E-cad-
herin expression. E-cadherin is a classical member of the
cadherin family, whose extracellular domain facilitates
homotypic intercellular adhesions while the cytosolic tail
assembles catenins and other signaling and scaffolding
molecules at the membrane to link to the actin cytoskele-
ton [10,11]. E-cadherin-mediated cell-cell adhesions limit
cell motility and establish apical-basal polarity. The loss
of E-cadherin expression and disassembly of E-cadherin
adhesion plaques on the cell surface enables tumor cells
to disengage from the primary mass and move to con-
duits of dissemination [12]. This duality of functional-
ities--intercellular cohesion and regulation of
intracellular signaling cascades--suggests that E-cadherin
may impact multiple aspects of epithelial homeostasis.
Thus, E-cadherin expression is intimately connected to
a cell's degree of epitheliality - in both morphology and
migratory and invasive abilities. In cancer pathogenesis,
E-cadherin expression is dynamically regulated via epige-
netic mechanisms, specifically methylation of the pro-
moter, providing tumor cells the plasticity to switch
between EMT and MErT depending on the microenvi-
ronment [13]. Interestingly, it has been observed that
metastases often resemble the epithelial-like phenotype
of the primary tumor rather than the mesenchymal phe-
notype observed at the invasive front. In addition, several
pathological studies, including the one conducted herein,
have observed increased E-cadherin expression in metas-
tases compared to aberrant or loss of expression in the
primary tumors, further challenging the notion that EMT
is irreversible and suggesting that E-cadherin may be
involved in MErT at the metastatic site [14,15]. However,
one limitation of these pathological studies is that it is
impossible to determine whether these E-cadherin-posi-
tive metastases result from the rare escape and expansion
of epitheloid carcinoma cells, such as in the cell coopera-
tivity model, or whether they arise from a mesenchymal-
like cell that has undergone a phenotypic reversion back
to a more differentiated phenotype, as we hypothesize
[16,17].
Therefore, we aimed to experimentally determine
whether it was possible for the mesenchymal-like MDA-
MB-231 breast cancer cells to undergo an MErT through
the re-expression of E-cadherin, either through exoge-
nous introduction or through induction by the microen-
vironment. Ectopic expression of E-cadherin in MDA-
MB-231 cells resulted in a reversion back to some degree
of the epithelial phenotype, particularly with respect to
morphology and functional suppression of migration and
invasion. Furthermore, introduction of breast cancer cells
and primary explants into a secondary organ environ-
ment led to the passive loss of methylation of the E-cad-
herin promoter and re-expression of this cell-cell
adhesion molecule, demonstrating a mechanism for this
reversion of EMT. In vivo experiments in mice revealed
similar results in lung metastases, suggesting that re-
expression of E-cadherin may be a critical step in meta-
static colonization of not only the liver but lung as well.
Results
E-cadherin is expressed in distant metastases of E-
cadherin-negative primary tumors
Loss of E-cadherin expression in the primary tumor is
correlated with poor prognosis and survival [14,18]. A
few studies have examined E-cadherin expression in the
primary tumor and distant metastases, but the cases ana-
lyzed in these studies included metastases to lymph
nodes or uncommon sites of breast cancer metastasis
[15]. To conduct our own survey focusing on metastases
to the most common sites, we obtained specimens of pri-
mary tumors and the corresponding metastases from 16
patients with infiltrating ductal carcinoma. Metastatic
sites from which tissue was obtained included the lung
(10 cases), liver (3), and brain (3). Both primary tumor
and metastases were immunostained for E-cadherin. E-
cadherin positive cells were counted based on high inten-
sity membrane or cytoplasmic staining. Percentage of E-
cadherin positivity was calculated as the number of E-
cadherin-positive cells over the total number of cancer
cells in each field (Additional file 1). Overall, 62% (10 of
16) cases showed increased E-cadherin expression in the
metastases compared to the primary tumors (Figure 1a),
with this being consistent across the various sites; 66% (2/
3) of liver metastases, 66% (2/3) of brain metastases, and
60% (6/10) of lung metastases exhibited increased E-cad-
herin expression. There was no correlation between hor-
m o n e  r e c e p t o r  o r  H e r 2 / n e u  s t a t u s  a n d  E - c a d h e r i n
expression. In some cases, closer examination of the
specimens revealed striking differences of E-cadherinChao et al. Molecular Cancer 2010, 9:179
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expression between the primary tumor and the metasta-
sis, with the primary tumor wholly negative and the
metastasis mostly positive for E-cadherin expression; one
such liver metastasis is shown (Figure 1b). E-cadherin
expression within both the primary tumors and the
metastases was often heterogeneous, which was
accounted for by quantifying areas of the tumor that best
approximated the heterogeneity observed in the sample.
However, even with this heterogeneity the levels of E-
cadherin positivity were increased in the metastases
(Additional file 1). In addition, the sizes of metastases
ranged greatly, from micrometastases less than 1 mm to
macrometastases greater than 2 cm in diameter. The
trend appeared likely that heterogeneity of E-cadherin
expression was positively correlated with tumor size;
however, due to our small sample size we were unable to
statistically assess such a correlation.
Of interest, E-cadherin expression in the metastases did
not appear to be random. Shown is a liver metastasis
demonstrating increased expression at the hepatocyte-
cancer cell interface and decreased expression centrally,
suggesting that E-cadherin is directly regulated by hepa-
tocyte interactions (Figure 1c). Quantification of staining
intensity confirmed an increase in E-cadherin expression
in the area outlined by the solid inset compared to the
area outlined by the dashed inset located further away
from hepatocytes (Figure 1d). E-cadherin staining in the
tissue samples is observed both at the membrane and in
the cytoplasm, as autocrine EGFR signaling generally
present in breast cancer drives E-cadherin internalization
[19,20]. This overview of a small number of paired speci-
mens provides insights into whether MErT is possible. If
metastases are the result of expansion of a clonal popula-
tion of cells originating from a primary tumor cell that
has undergone EMT, then one would expect metastases
to be E-cadherin-negative unless this phenotype is plas-
tic. The finding of E-cadherin-positive metastases sug-
Figure 1 E-cadherin expression is increased in metastases compared to primary tumors. A) Percentage of E-cadherin-positve cells is increased 
in metastases compared to the primary tumors. Organ sites of metastases are organized by color: liver (red), lung (blue), and brain (yellow) B) Example 
of a case showing strong expression of E-cadherin in the metastasis (right) compared to negative expression in primary (left). C) Heterogeneous ex-
pression of E-cadherin in the center (dashed inset) versus edge (solid inset) of a liver metastasis. "C" denotes tumor and "H" denotes hepatocytes. D) 
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gests that non-EMT cells can establish metastases or that
MErT at the metastatic site can occur.
Ectopic expression of E-cadherin partly reverts breast 
cancer cells towards an epithelial phenotype
The finding of more prevalent E-cadherin expression in
metastases compared to the paired primary tumors led to
the question of whether the positive metastatic foci arose
from expansion of E-cadherin-positive cells or from
MErT of originally E-cadherin-negative cells. Thus, we
aimed to determine whether it was possible for the mes-
enchymal-like MDA-MB-231 breast cancer cells to
become more epithelioid following expression of E-cad-
herin. In MDA-MB-231 cells, E-cadherin expression is
suppressed by methylation of the promoter. We stably
transfected full-length E-cadherin driven by a CMV pro-
moter and generated single cell clones (231-Ecad). In
addition, because the possibility of intermediate EMT/
MErT phenotypes has been proposed, we also stably
transfected MDA-MB-231 cells with a construct com-
posed of the intracellular and transmembrane domains of
E-cadherin coupled to the class I major histocompatibil-
ity complex antigen (H-2kd) extracellular domain (231-
H2kd). Such a construct was originally used to examine
the contribution of internal E-cadherin signaling in the
absence of E-cadherin-mediated intercellular interactions
[21,22]. We postulated that expressing only the cytosolic
tail of E-cadherin would allow for a partial MErT through
the intracellular sequestration of adherens junction com-
ponents and other effector proteins that is observed in
epithelial cells but absent in mesenchymal cells. Immuno-
blot and immunofluorescence confirmed the exogenous
expression of E-cadherin and E-cadherin-H2kd in MDA-
MB-231 cells (Figure 2 and Additional file 2). 231-Ecad
and 231-H2kd mutants display colocalization with the
catenins at the membrane (Additional file 2b). E-cadherin
expressing MCF7 breast cancer cells were used as a posi-
tive control. 231-Ecad cells exhibited cobblestone or cell-
cell clustered morphology and formed cell contacts,
which was not observed in control transfected MDA-
MB-231 cells. 231-H2kd cells demonstrated a more flat-
tened morphology that did not fully resemble either epi-
thelial or mesenchymal phenotypes (Figure 2a). As
expected, 231-H2kd cells did not form cell-cell contacts.
It is important to note that this culture was performed at
low cell density, so that cells were limited in establishing
cell-cell connections. Thus, outside-in signaling mediated
by E-cadherin was not necessary for the morphology
change.
We next analyzed the expression of epithelial and mes-
enchymal markers in the various cell lines to monitor the
penetrance of the epithelial/mesenchymal phenotypes.
We evaluated the expression of a spectrum of cytokera-
tins including cytokeratin-18 (CK-18), the primary inter-
mediate filament present in epithelial cells. Expression of
vimentin, smooth muscle actin, and fibronectin were
used as markers of the mesenchymal phenotype. Loss of
cytokeratins and increased expression of vimentin,
smooth muscle actin, or fibronectin have been shown to
occur concurrently with EMT in adenocarcinomas [23].
The survey of these epithelial and mesenchymal markers
revealed that 231-Ecad cells demonstrated decreased
expression of smooth muscle actin, fibronectin, and
vimentin and increased expression of cytokeratins (Fig-
ures 2b and 2c). Upregulation of N-cadherin has been
observed in EMT, but because N-cadherin is not
expressed in MDA-MB-231 cells this mesenchymal
marker was not tested. 231-Ecad cells displayed increased
cytokeratin-18 and decreased vimentin expression as
assayed by immunofluorescence (Figure 2c). As epithelial
and mesenchymal cells also differ in their cytosketelal
architecture, phalloidin was used to visualize the actin
cytoskeleton. Expression of the entire E-cadherin mole-
cule (231-Ecad) provided a more epithelial-like reticular
actin filament meshwork (Figure 2c). The persistence of
mesenchymal markers and failure to fully express epithe-
lial markers in 231-Ecad cells compared to the epithelial
MCF7 cells suggests that MDA-MB-231 cells transfected
with E-cadherin (either wild-type or cytosolic tail) still
maintain some aspects of mesenchymal phenotype.
Mesenchymal and epithelial phenotypes also confer
functional behaviors on tumor cells. As such we tested
the two key properties related to tumor escape enabled by
EMT: migration and invasion. After an in vitro scratch
assay, which measures migration, we observed that
expression of full-length or the cytosolic region of E-cad-
herin resulted in suppressed migration almost down to
low levels noted for the epithelial MCF7 cancer line (Fig-
ure 3a). Similar trends were observed in the Matrigel
invasion assay, which integrates motility with other prop-
erties such as matrix remodeling to better recreate the
movement through bioactive matrices that defines tumor
invasion. The invasive ability of both 231-Ecad and 231-
H2kd cells was suppressed compared to MDA-MB-231
cells (Figure 3b). That suppression of migration and inva-
siveness were observed in 231-H2kd cells in the absence
of changes in expression in the marker genes suggests
that these functional behaviors may be independent of a
mesenchymal to epithelial transition. While 231-H2kd
cells may be similar to wildtype 231 in terms of mesen-
chymal and epithelial gene expression, β-catenin localiza-
tion differed (Additional file 2); while 231 cells exhibit
cytoplasmic distribution of β-catenin, 231-H2kd cells
localize α-catenin, β-catenin, and p120 to the cell mem-
brane as do the epithelial counterparts 231-Ecad and
MCF7 cells. As reported by other groups, this alteration
alone is sufficient to account for the invasion suppressor
phenotype [24].Chao et al. Molecular Cancer 2010, 9:179
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Figure 2 E-cadherin expression alters cell morphology. A) Cell morphology as examined by phase contrast microscopy (left column) and E-cad-
herin expression (red) as detected by immunofluorescence (right column) B) Immunblot analysis illustrates ectopic expression of E-cadherin in 231-
Ecad cells as well as expression of various epithelial and mesenchymal markers in the E-cadherin mutants. C) Immunofluorescence of vimentin, cytok-
eratin-18 and actin cytoskeleton (rhodamine phalloidin). Shown are representative of at least three different assessments using one of two indepen-
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In summary, these results indicate that expression of
exogenous E-cadherin (wild-type or cytosolic tail) in
MDA-MB-231 cells results in a morphological shift
toward the epithelial end of the spectrum. The expression
of both epithelial and mesenchymal markers in 231-Ecad
and 231-H2kd cells demonstrate that these cells may not
have undergone a complete MErT, but the migration and
invasion assay data suggest that expression of the full-
length and cytosolic domains of E-cadherin are sufficient
to induce a more epithelial-like phenotype in terms of cell
motility and invasiveness. Furthermore, suppression of
invasion and migration in 231-H2kd was comparable to
the suppression in 231-Ecad cells, indicating that changes
to the localization of key signaling proteins during the
mesenchymal to epithelial transition can have profound
effects in mitigating the mesenchymal nature of an inva-
sive cell.
E-cadherin expression is induced by a secondary organ 
microenvironment
Our previous results demonstrating E-cadherin expres-
sion in metastases suggested that a reversion to a more
epithelial phenotype could occur at the metastatic site.
We therefore hypothesized that a secondary organ
microenvironment could induce re-expression of E-cad-
herin. To test this hypothesis, we cultured MDA-MB-231
cells with rat hepatocytes, as the liver is one of the main
organs to which breast cancer cells metastasize. After 6
days of culture, expression of E-cadherin was detected
using a human specific E-cadherin antibody (Figure 4a).
Control experiments confirmed that the human-specific
antibody did not cross-react with E-cadherin of rat ori-
gin, indicating that the E-cadherin was re-expressed by
MDA-MB-231 cells (data not shown). Expression was
also detected by flow cytometry (Figure 4b). Side and for-
ward scatter as well as hepatocyte-specific autofluores-
cence gating were used to exclude the hepatocyte
population. Flow cytometry analysis of MDA-MB-231
cells after 6 days of co-culture with hepatocytes formed a
bimodal distribution, with 22.32% of cells forming a dis-
tinct population of E-cadherin positive cells. Culture of
MDA-MB-231 cells in hepatocyte growth media alone
did not result in re-expression, indicating that the re-
expression is driven by hepatocytes (Figure 5c). Increased
expression of E-cadherin mRNA was also detected by
qRT-PCR (Figure 5d). After 6 days of culture with hepato-
cytes, MDA-MB-231 exhibited levels of E-cadherin tran-
script comparable to E-cadherin-positive MCF7 cells,
while MDA-MB-231 cells cultured in the absence of
hepatocytes presented undetectable mRNA levels. The
fact that the E-cadherin mRNA level appears to be similar
to that in MCF-7 cells despite lower protein levels is likely
due to autocrine EGFR signaling driving E-cadherin
internalization and degradation [15].
Figure 3 E-cadherin expression suppresses migration (A) and invasion (B). Cell migration was analyzed using a scratch assay. Scratch closure was 
measured over a period of 24 hours and the fraction closure was quanitified by Metamorph software (n = 3). Invasion was measured in using a Matrigel 
invasion assay in which cells were allowed to migrate through a Matrigel-coated transwell insert for a period of 24 hours. N = 3 in triplicate; mean ± 
s.e.m. Results shown are representative of one of two independent clones of each mutant.
* *
*
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Figure 4 Hepatocytes drive the re-expression of E-cadherin in MDA-MB-231 breast cancer cells. A) Immunoblot of proteins lysates from MDA-
MB-231/hepatocyte co-cultures using a human-specific antibody. B) Flow cytometry of the MDA-MB-231 population using a human-specific antibody 
shows a unimodal population on day 0 and a bimodal population on day 6. C) MDA-MB-231 cells do not express E-cadherin without hepatocytes. D) 
RT-PCR using human-specific primers of MDA-MB-231 cells after 6 days of co-culture with hepatocytes. Means (n = 4) ± s.d. Note that species-specific 
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To prevent re-expression of E-cadherin in coculture
and to validate that the changes noted were from E-cad-
herin and not another undefined co-expressed protein,
we stably transfected MDA-MB-231 cells with an E-cad-
herin shRNA plasmid construct and generated single cell
clones (231-shEcad). In addition, breast carcinoma cells
were RFP-labeled to more easily discriminate cancer cells
from hepatocytes in coculture. While MDA-MB-231,
231-H2kd, and 231-Ecad cells reverted to an epithelial
clustered morphology following hepatocyte coculture,
231-shEcad cells remained fibroblastic (Figure 5). Immu-
nofluorescence confirmed that the shRNA construct pre-
vented re-expression of E-cadherin (Figure 6, left
column). To evaluate whether MErT occurs following E-
cadherin re-expression, cocultures were immunostained
for the mesenchymal marker vimentin. Just as expression
of mesenchymal markers persisted in 231-Ecad cells, E-
cadherin re-expression in coculture did not completely
suppress expression of vimentin (Figure 6, right column).
However, vimentin expression appeared more heteroge-
neous, with some cells expressing more than others. It is
important to note that compared to 231-Ecad cells where
E-cadherin was exogenously expressed, there may be
other unexplored molecular changes in MDA-MB-231
cells following hepatocyte coculture besides E-cadherin
re-expression.
As we demonstrated that it was possible for mesenchy-
mally-transitioned carcinoma cells to revert to a more
epithelioid phenotype, we next tested whether primary
explants of human breast tumors could also re-express E-
Figure 5 Breast cancer cells cultured with hepatocytes revert to 
an epithelial morphology. Phase contrast images of 231, 231-H2kd, 
231-Ecad, and 231-shEcad breast cancer cells cultured with rat hepato-
cytes for 6 days.






























50 M 50 M
Figure 6 Breast cancer cells culture with hepatocytes re-express 
E-cadherin but maintain vimentin A) Immunostaining of RFP-la-
beled breast cancer cells in hepatocyte coculture; E-cadherin 
(green), RFP (red), DAPI (blue) B) Immunostaining for vimentin 
(green), RFP (red), DAPI (blue). Shown are representative of at least 
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cadherin in hepatocyte coculture. Explants were obtained
from breast tumors without current evidence of dissemi-
nation and cultured for at most 3 passages prior to exper-
imentation. In total, four cocultured primary explants
were assayed by flow cytometry and seven primary
explants were analyzed by immunofluorescence following
hepatocyte coculture. Analysis by flow cytometry indi-
cated that although initially E-cadherin negative, one of
the four explants tested expressed E-cadherin after cocul-
ture (Figure 7a). Similarly, tumor cells in two of seven
e x p l a n t s  t h a t  w e r e  o r i g i n a l l y  E - c a d h e r i n  n e g a t i v e ,
expressed robust and well-localized E-cadherin after 6
days of co-culture with the hepatocytes (Figure 7b). We
were unable to ascertain the promoter methylation status
in these cells due to the limited number and passage
integrity of the primary cells; nonetheless, this line of evi-
dence strongly suggests that primary human breast can-
cer cells may undergo similar molecular changes as
MDA-MB-231 cells when cultured in a hepatic microen-
vironment.
E-cadherin re-expression in the liver microenvironment is 
due to loss of promoter methylation
In the absence of hepatocytes, E-cadherin expression in
MDA-MB-231 cells is transcriptionally repressed by
methylation of the E-cadherin promoter. Most intraduc-
tal breast carcinomas in which E-cadherin is downregu-
lated also exhibit similar promoter hypermethylation
[25]. Therefore loss of promoter methylation was exam-
ined as a possible mechanism for the re-expression of E-
cadherin. We assayed a CpG island that was proximal to
the E-cadherin transcription start site, whose methyla-
tion correlates inversely with E-cadherin expression [26].
Following coculture, total genomic DNA was isolated for
methylation-specific PCR (MS-PCR) [27]. Species-spe-
cific primers were used to guarantee measurement of
CpG methylation in only the human cancer cells and not
rat hepatocytes. When human MDA-MB-231 cells were
co-cultured with rat hepatocytes over a period of 6 days,
the methylation status of the E-cadherin promoter region
changed from a hypermethylated state to a hypomethy-
lated state (Figure 8a). However, in the absence of hepato-
cytes, MDA-MB-231 cells remained hypermethylated
(Figure 9a). To capture the dynamic loss of methylation of
the CpG sites along the length of the E-cadherin pro-
moter region, bisulfite sequencing was performed on
MDA-MB-231 cells. MCF7 cells were used as an unmeth-
ylated control for E-cadherin promoter analysis. As
expected, the promoter regions of the MDA-MB-231
cells were highly methylated before co-culture with hepa-
tocytes, as denoted by the filled in circles of the control
row. After coculture, much of the methylation was lost
from these specific CpG islands (Figure 8b). Thus, the
bisulfite sequencing validates our MS-PCR results and
shows that E-cadherin promoter methylation decreases
upon co-culture with hepatocytes, resulting in re-expres-
sion.
Because cancer cells are often globally hypomethylated,
we evaluated whether the loss of methylation was specific
to the E-cadherin promoter or the result of global
hypomethylation. The H19 gene is a paternally imprinted
gene whose methylation is modulated during gametogen-
esis and does not change after terminal differentiation of
a cell line [28]. We performed bisulfite MS-PCR analysis
on MDA-MB-231 cells before coculture and following
1,3, and 6 days of coculture with hepatocytes, examining
a previously reported CpG site of H19. Evaluation of the
data revealed that the average methylation of H19
remained unchanged at all time points indicating that
global hypomethylation is not responsible for the changes
observed at the E-cadherin promoter (Figure 9b).
Figure 7 A subset of primary breast carcinoma explants re-ex-
press E-cadherin when cocultured with primary hepatocytes. A) 
Flow cytometry analysis of primary explants using a human-specific E-
cadherin antibody. A fluorescence unit of 1 indicates that the fluores-
cence intensity was equal to the same gate performed without addi-
tion of antibody. B) Confocal microscopy of two positive explants. 
Explants (C), hepatocytes (H). Human-specific E-cadherin, blue; actin, 
red; nuclei, green.
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Figure 8 Breast cancer cells lose methylation of E-cadherin promoter methylation following hepatocyte coculture. A) Nested PCR method to 
detect methylation status of the E-cadherin promoter in a six day time course of hepatocye coculture. Above, bisulfite-treated DNA is amplified with 
primers that exclude CpG islands to amplify a 270 bp region independent of methylation status. Below, nested primers anneal to the 270 bp target 
to amplify a methylated (112 bp) or unmethylated (120 bp) fragment in the six day time course. MCF7 is used an unmethylated control. B) Bisulfite 
sequencing of CpG islands in the E-cadherin promoter. Figure adapted from Corn et al . CpG islands are indicated as vertical lines on map; each CpG 
island is represented a circle. MCF7, MDA-MB-231, and MDA-MB-435 were sequenced on days 1,3, and 5 coculture. Open circle, unmethylated CpG; 
closed circle, methylated CpG; filled circle, mixed quality values.
Total cancer cell and hepatocyte DNA isolated from coculture





Loss of promoter methylation can result from either a
passive mechanism (lack of maintenance methylation
subsequent to mitosis) or an active mechanism (enzyme-
mediated excision), though there are currently no well-
defined demethylases. The presence of intermediate
stages of promoter methylation on day 3 and extended
time period to unmethylated status (6 days) suggested a
passive mechanism. To test whether the loss of methyla-
tion was dependent on proliferation of the cancer cells,
we inhibited proliferation of the cancer cells with mito-
mycin-C. This treatment completely prevented loss of
methylation of the promoter as demonstrated by MS-
PCR (Figure 9c). Furthermore, addition of mitomycin-C
also prevented re-expression of E-cadherin at the proteinChao et al. Molecular Cancer 2010, 9:179
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level (Figure 9d). Inhibition of DNA methyltransferases,
which mediate CpG island methylation, could also
account for loss of methylation. However, immunostain-
ing for DNA methyltransferase DNMT1 showed neither
decrease in expression nor change in nuclear localization
(Figure 9e). Taken together, these data point to passive
loss of methylation as the mechanism by which E-cad-
herin is re-expressed.
E-cadherin re-expression occurs in vivo
To determine whether reversion of E-cadherin repression
could be induced in vivo, we injected MDA-MB-231 cells
into the mammary fat pads of mice. Mice were sacrificed
after four weeks, to allow for dissemination from the pri-
mary tumor. Because MDA-MB-231 cells inoculated into
the mouse mammary fat pad mainly metastasize to lung
and not to liver when allowed to spontaneously metasta-
size, mice were examined for lung metastases by histo-
pathological examination of the tissues. Our use of
human breast cancer cells in a mouse host allowed for a
human-specific E-cadherin antibody to discern the
source of E-cadherin expression between the cancer cells
and the epithelial mouse parenchyma. We first confirmed
that the primary xenograft transplants in the inguinal
mammary fat pads did not express E-cadherin (Figure
10a, left panel). There was no change in E-cadherin status
of the invading cells in the primary xenograft, as we
observed both the central and peripheral areas of the
tumor to be devoid of E-cadherin as detected by immu-
noperoxidase staining (Figure 10a, middle and right pan-
els). Two representative images of lung micrometastases
less than 2 mm in diameter showed a markedly different
pattern of E-cadherin expression. When immunoperoxi-
dase labeling was performed on these sections, isolated
islands expressing E-cadherin localized to the cell mem-
brane were detected (Figure 10b). The human-specific
antibody identified the disseminated MDA-MB-231 cells
with robust E-cadherin expression, while not labeling the
surrounding mouse lung tissue. Other fields of the same
lung, unaffected and clear of metastatic lesions, did not
display positive staining. Although we were unable to
obtain metastases to the liver in the animal model, E-cad-
herin re-expression was observed in lung metastases in
both the animal model and in clinical samples, suggesting
that re-expression of E-cadherin may not be limited to
the liver microenvironment.
Discussion
Paget's seed and soil hypothesis has long postulated that
cancer cells, or the "seeds", will only grow in a specific
microenvironment, or "soil" [24,29-31]. Indeed, despite
the fact that tumors are continually shedding cells, very
Figure 9 Re-expression of E-cadherin follows a proliferation-dependent demethylation of the E-cadherin promoter. A) MS-PCR of MDA-MB-
231 cultured alone in hepatocyte growth media B) MS-PCR using human-specific primers that amplify the imprinted H19 gene. C) MS-PCR of E-cad-
herin promoter following addition of MMC D) Addition of MMC prevents E-cadherin re-expression at the protein level. E) The maintenance demeth-
ylase DNMT1 does not change in localization or intensity in MDA-MB-231 cancer cells when cocultured with hepatocytes. DNMT1, red; DAPI, blue.
A B
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few circulating tumor cells actually establish metastases,
suggesting that post-extravasation survival is a crucial
rate-limiting step [32]. The clinical observations that
breast cancer displays a characteristic pattern of metasta-
sis, specifically to the lung, liver, bone, and brain, indicate
that these organs provide the most conducive microenvi-
ronment for metastatic growth. In addition, cancer cells
themselves may exhibit an inherent gene signature pre-
disposing them to homing to a particular organ site
[14,18]. The precise environmental factors that enable the
organotropism of metastases are yet to be fully discov-
Figure 10 E-cadherin positive metastatic foci originate from E-cadherin negative primary tumors. A) Left, human MDA-MB-231 breast cancer 
cell xenograft in a mouse inguinal fat pad (H&E); middle, human-specific E-cadherin antibody indicates the absence of E-cadherin expression in the 
center of the primary tumor; right, absence of human-specific E-cadherin labeling at the periphery of the tumor. B) Micrometastases in the lung orig-
inating from the primary xenograft in A. Immunoperoxidase labeling of diseased portions of the mouse lung indicate the presence of human E-cad-
herin-positive MDA-MB-231 cancer cells; bottom adjacent.
A
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ered, but even less well known is why only a tiny fraction
of circulating carcinoma cells form metastases.
P r i o r  t o  e x t r a v a s a t i o n ,  c a n c e r  c e l l s  m u s t  s u r v i v e
through invasion and emigration, anchorage-indepen-
dent dissemination, and extravasation into the ectopic
organ. These behaviors are thought to be conferred by
molecular changes as a result of EMT. However, post-
extravasation, cancer cells encounter a new set of chal-
lenges, notably integration within organ parenchyma and
establishment of blood supply, which mesenchymal-like
cells appear poorly equipped to handle. Despite the
importance of EMT in promoting metastatic progression,
there is mounting evidence that EMT is not an irrevers-
ible switch in cancer cell phenotype. Analysis of primary
tumors and their corresponding metastases reveal that
even though an EMT may have occurred to engender
metastases, the phenotypes of the two can be strikingly
similar. E-cadherin expression has been detected in
lymph node and non-nodal metastases in carcinomas not
limited to breast [33]. Re-expression of adhesion mole-
cules could therefore be one way in which the secondary
organ microenvironment promotes survival of metastatic
cells as cadherin-cadherin engagement promotes activa-
tion of cell survival signaling pathways [19].
To ascertain whether these earlier reports of E-cad-
herin-expressing metastases held for intraductal breast
carcinomas, we surveyed a small set of matched primary
and metastatic tumors. Some 2/3 of metastases to the
lung, liver, or brain expressed increased E-cadherin com-
pared to the primary tumors, which largely exhibited
aberrantly low to negative E-cadherin expression. Not all
m e t a s t a s e s  e x h i b i t e d  h i g h  l e v e l s  o f  E - c a d h e r i n  e x p r e s -
sion, which is not surprising as metastases are known to
evolve and give rise to further disseminations, suggesting
that a second EMT may occur within more aggressive
nodules.
Interestingly, E-cadherin expression even within metas-
tases was heterogeneous, with increased E-cadherin
expression seemingly correlated with proximity to nor-
mal parenchymal cells. This heterogeneity suggests that
constant interaction with hepatocytes in liver may be
necessary. Still, despite these observations, it was possible
that these E-cadherin-positive tumor cells disseminated
from the primary tumor as epithelioid cells and formed
secondary metastatic lesions. Thus, we sought to provide
proof-of-principle that cancer cells could be engineered
to approach a mesenchymal-to-epithelial reverting tran-
sition by altering E-cadherin expression, either exoge-
nously or via the microenvironment. We first
hypothesized that we could engineer a MErT in MDA-
MB-231 cells by expressing wild-type E-cadherin or by
sequestering the E-cadherin-associated catenins with a
non-binding E-cadherin construct. After transfecting the
MDA-MB-231 cells with the cytosolic domain of E-cad-
herin linked to the MHC external domain, we saw that
the dominant negative protein sequestered α-, β- and
p120-catenins. The advantage of using this dominant
negative is that the catenin signaling could be parsed
from other activities of the extracellular domain of E-cad-
herin including cell adhesion through trans-ligation and
EGFR cis-modulation [23,34,35]. While neither construct
could completely revert MDA-MB-231 cells to an epithe-
lial phenotype, expression of either construct resulted in
morphological transformations and behavioral changes
noted as suppression of migration and invasion. Our
results also corroborate the findings of other studies
focusing on the role of E-cadherin as a tumor or invasion
suppressor [36-38].
When cultured in a hepatic microenvironment, MDA-
MB-231 exhibited a similar reversion to an epithelial phe-
notype, both in morphology and E-cadherin re-expres-
sion. The nature of the signals that drive the reversion
back to an epithelioid phenotype are not known and
likely to be complex. Initial studies found that neither
conditioned media nor hepatocyte-derived matrix could
trigger E-cadherin re-expression in this breast carcinoma
line, though the combination of the two was noted to lead
to a weak re-expression of E-cadherin (data not shown).
Re-expression secondary to loss of methylation of the E-
cadherin promoter was also observed in the cell line
MDA-MB-435 (Additional file 1), which is now consid-
ered to be a melanoma derivative, but is nonetheless use-
ful as this neurectodermal lineage expresses E-cadherin
as melanocytes but loses expression during melanoma
progression [39]. Furthermore, this reversion is not likely
unique to the liver microenvironement, based on the
findings in human metastases and in our in vivo mouse
model. Recently, we have found that lung parenchymal
cells can drive E-cadherin expression in prostate tumor
cells [40]. A recent study suggests that laminin-1 may be
one component of the extracellular matrix that contrib-
utes to E-cadherin re-expression [15]. One key difference
between our studies is the microenvironment used to
induce E-cadherin re-expression in MDA-MB-231 cells.
While Benton et al used a three-dimensional laminin-1
hydrogel, we chose to simulate a secondary organ
microenvironment by culturing breast cancer cells with
hepatocytes, thereby exposing them to hepatocyte-
derived soluble factors and extracellular matrix. Their
finding of DNMT1 downregulation as the mechanism for
E-cadherin expression was not observed in our system
(data not shown), suggesting that tissue architecture may
induce MErT by alternative mechanisms. Thus, the
search for this signaling 'cocktail' is likely to be complex
and lies beyond the scope of the present communication.
T h a t  E - c a d h e r i n  r e - e x p r e s s i o n  i s  c a u s e d  b y  l o s s  o f
methylation suggests a functional mechanism by which
the microenvironment modulates the mesenchymal toChao et al. Molecular Cancer 2010, 9:179
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epithelial phenotypic switch. E-cadherin is predomi-
nantly downregulated in carcinomas at the post-transla-
tional and/or transcriptional levels. Regulation of E-
cadherin is therefore unique among tumor suppressors in
which loss or mutation appears to be the rule, but this
epigenetic regulation of E-cadherin allows for increased
phenotypic plasticity. We have previously reported that
prostate cancer cells cultured with hepatocytes also re-
express E-cadherin, but as a result of inhibition of the
EGF receptor signaling [24,35,41,42]. However, in breast
cancers E-cadherin is silenced directly at the transcrip-
tional level by promoter hypermethylation or indirectly
through its transcriptional suppressors Snail, Slug, and
Twist [43]. No differences in expression of these tran-
scriptional suppressors were observed following hepato-
cyte coculture (data not shown). In MDA-MB-231 cells,
representative of the basal subtype of infiltrating ductal
carcinomas, the CpG islands in the promoter region most
proximal to the E-cadherin initiation site are fully methy-
lated, which exerts a profound effect on mesenchymal
nature. Demethylation of these islands by the chemical
agent 5-aza-deoxycytidine causes re-expression of E-cad-
herin and loss of invasive ability [44-47]. Coculturing of
MDA-MB-231 cells with primary hepatocytes resulted in
loss of methylation of the E-cadherin promoter and
expression of E-cadherin mRNA and protein. We
observed that the loss of methylation was dependent on
the proliferation of the cancer cells. This finding was not
unique to the breast carcinoma cells, as the MDA-MB-
435 line also demonstrated loss of promoter hypermethy-
lation upon coculturing with hepatocytes. Importantly,
this loss of methylation was at least semi-specific and not
global as the imprinted H19 gene remained methylated.
The ubiquitous transcription factor Sp1 has been impli-
cated in the regulation of methylation status by binding
loci of hemimethylated DNA, protecting sequences from
de novo methylation, preferential demethylation, or pas-
sive demethylation mechanisms [48]. Sp1 was necessary
for loss of methylation in coculture (data not shown),
strongly suggesting active signaling from the microenvi-
ronment.
The foundation of our findings rest on the epigenetic
reversion observed when breast cancer cells are cocul-
tured with primary hepatocytes. The epigenetic status of
the primary tumor and disseminated metastases is most
likely important, since primary tumors that have high E-
cadherin levels have very little systemic disease [31,49],
suggesting that the epigenetic reversion at distant sec-
ondary sites is also relevant. The xenograft model in
which E-cadherin negative MDA-MB-231 cells formed E-
cadherin-negative primary tumors in the mammary fat
pads but E-cadherin-positive micrometastases and the
finding that at least some E-cadherin-negative primary
breast carcinoma cells can re-express this molecule sup-
port the idea that this reversion is possible. Furthermore,
the xenograft experiment demonstrates that the molecu-
lar changes can occur in the secondary site. However,
these experiments do not mean that all E-cadherin-posi-
tive metastases necessarily arise from the reversion of E-
cadherin-negative cancer cells. Further molecular dissec-
tions and a much larger breast tumor survey, challenging
due to the paucity of matched primary and non-nodal
metastases, are needed to determine the extent of this
MErT in early metastatic seeding.
The potential implications of E-cadherin re-expression
and MErT are many. There are several possible outcomes
or combinations of outcomes after a cell extravasates into
a metastatic target tissue: apoptosis, dormancy, or sus-
tained proliferation, with the latter appearing the rarest
[50]. While E-cadherin typically mediates homotypic cell-
cell adhesions, heterophilic ligation between different cell
types has been documented [51-53]. Cancer cell adhesion
has been shown to facilitate extravasation and coloniza-
tion of distant organs [54,55]. Phenotypic reversion to
epitheliality in vivo may therefore enhance the integration
and survival of cancer cells at the metastatic site by cloak-
ing the cancer cell with epithelioid-like characteristics, or
may act to transmit mitogenic signals. E-cadherin expres-
sion has also been shown to suppress cell growth, which
may account for the dormancy period between clinical
presentation of metastases [56]. However, preliminary
results in a parallel study reveal that one important sur-
vival advantage conferred by E-cadherin expression is
increased resistance to cell death induced by chemother-
apeutic agents such as camptothecin, doxorubicin, and
taxol (data not shown). Cellular adhesion has long been
implicated in intrinsic or acquired resistance of solid
tumors to multiple anticancer therapeutics not restricted
to chemotherapy [57,58]. The addition of E-cadherin
function blocking antibodies sensitizes multicellular
spheroids to treatment with various chemotherapeutic
agents and E-cadherin-positive cells are more resistant to
staurosporine-induced cell death than E-cadherin-nega-
tive breast cancer cells [20]. A similar survival advantage
may be conferred when disseminated cells face apoptotic
cytokines, thus providing a selective pressure that then
confounds adjuvant therapies. The finding that E-cad-
herin re-expression and catenin sequestration can con-
tribute to a MErT suggests that they may be appropriate
therapeutic targets for preventing the establishment of
metastases in breast cancer.
Materials and methods
Generation of cell lines
231-H2kd cells were generated using the Myc/His encod-
ing H-2kd-E-cad dominant negative E-cadherin con-
struct, a kind gift from Vizirianakis et al [15]. 231-H2kd
cells were selected by FACS using the H-2kd (SF1-1.1)Chao et al. Molecular Cancer 2010, 9:179
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antibody (BD Pharmingen; San Jose, CA) and were main-
tained in 900 μg/ml G418 until used for experimentation.
231-Ecad cells were made by co-transfecting a plasmid
encoding the E-cadherin full-length cDNA sequence
(Open Biosystems) with the pcDNA 3.1 plasmid (Invitro-
gen) and cultured in 900 μg/ml G418 to select for stable
transfectants. 231-shEcad cells were generated using an
E-cadherin shRNA plasmid (Santa Cruz Biotechnology)
and stable transfectants were selected using 5 ug/ml of
puromycin and confirmed by RT-PCR. At least two single
cell clones of each mutant were generated by selecting for
resistance to G418 (231-H2kd and 231-Ecad) or puromy-
cin (231-shEcad). Control clones transfected with
pcDNA 3.1, DsRed2, and control shRNA were also gener-
ated and tested. Single cell clones of each mutant line
were subsequently transfected with the DsRed2 plasmid
vector and FACS sorted for RFP fluorescence for use in
hepatocyte cocultures. In all cases the experiments were
performed at least once with the different clones, render-
ing similar results.
Cell culture and co-culture
MCF7, MDA-MB-231, and MDA-MB-435 cells were cul-
tured in RPMI-1640 with 10% FBS as previously
described [15]. Primary rat hepatocytes were isolated by
collagenase perfusion and cultured as described previ-
ously [59] and plated onto collagen-coated 6-well plates
at 60,000 cells/cm2. The following day, cancer cells were
seeded onto the hepatocyte monolayer at 3,000 cells/cm2
and cocultured for 6 days.
Immunohistochemistry
Paraffin-embedded patient samples were obtained from
Magee Womens Hospital. Sections underwent antigen
retrieval in citrate solution and were incubated with E-
cadherin primary antibody (Cell Signaling). Antigen
staining was performed using DAB (Vector Laboratories)
then counterstained with Mayer's hematoxylin. Second-
ary antibody alone served as a negative control and adja-
cent normal tissue served as an internal positive control.
Images of three randomly-selected microscope fields of
each sample were taken and the percentage of E-cadherin
positive cancer cells was quantified as the number of E-
cadherin positive cells over the total number of cancer
c e l l s  i n  t h a t  i m a g e .  M i c r o s c o p e  f i e l d s  s h o w n  w e r e
selected to account for the heterogeneity of each sample.
Relative staining intensity of the liver metastasis was
quantified using ImageJ software.
Invasion assay
Invasive potential was determined in vitro by migration
through an artificial ECM [26]. 2.5 × 104 cells were chal-
lenged in growth-factor reduced matrigel invasion cham-
bers (BD Biosciences). Cells were seeded into the top
chamber with serum-free media and media containing
10% serum was added to the lower chamber for the
remainder of the assay. After 24 hours, the remaining
cells and ECM in the top chamber were removed by cot-
ton swab. Cells that invaded through the matrix to the
bottom of the filter were then fixed and stained with
DAPI and counted. Individual experiments were per-
formed in triplicate.
Scratch Assay
A monolayer of cells was grown to confluence in a 6-well
plate and at experimental time zero a scratch was made in
each well using a pipette tip. The well was imaged at time
zero and again 24 hours later. Using Metamorph, a mea-
surement was taken for how much the denuded area had
filled in the 24-hour period.
Xenografts
The Institutional Animal Care and Use Committee at the
Veterans Affairs Hospital in Pittsburgh approved all ani-
mal procedures. Experiments were performed in 8 week
old female athymic nude mice. One million MDA-MB-
231 cells were injected into the right mammary fat pad;
injection vehicle was the culture medium (0.2 mL/site).
Mice were sacrificed 4-5 weeks after tumor cell implanta-
tion and the primary xenograft and lungs removed.
Xenograft and other harvested tissues were fixed in 4%
buffered formalin and 4 μm thick paraffin sections under-
went antigen retrieval for 5 min in 95°C 10 mM citrate
solution in preparation for H&E and immunochemistry.
With the use of the Mouse on Mouse Kit (Vector Labs,
Berlingame, CA), positive labeling was confirmed by
comparing serial sections incubated with the primary
human-specific E-cadherin antibody (67A4 1:100; Santa
Cruz Biotechnology, Santa Cruz, CA) or the biotinylated
secondary antibody alone. Labeling was visualized with
the Vectastain Elite kit (Vector Labs).
Methylation Specific PCR and bisulfite sequencing
DNA was isolated from co-culture using the DNeasy
Blood and Tissue Kit (Qiagen, Velencia, CA). 2000 ng of
isolated DNA was subjected to bisulfite treatment using
the EZ DNA Methylation Gold Kit (Zymo, San Diego,
CA) per the manufacturer's specifications. MSP was per-
formed in the way of Corn et al [60] or using the CpG
WIZ E-cadherin Amplification Kit per the manufac-
turer's instructions (Millipore, Temecula, CA). Briefly, in
the method of Corn, a nested PCR method was used, in
which the first primer set generated a 270 bp fragment
that was subsequently sequenced. The second round of
PCR used either nested primers that were specific to
either the unmethylated or methylated allele, which
amplified the first CpG island after the transcription start
site. The product size of the methylated reaction was 112
bp and 120 bp for the unmethylated.Chao et al. Molecular Cancer 2010, 9:179
http://www.molecular-cancer.com/content/9/1/179
Page 16 of 18
MSP of H19 after bisulfite conversion was performed
using the following primers: F 5'-TTA TAA AAT CGA
AAA TTA CGC GCG A-3' R 5'-TTT TAG ATG ATT
TTT GTG AAT TTT-3'. Cycling conditions were 95°C
for 15 min, 35 cycles of 94°C for 1 min, 55°C for 1 min,
and 72°C for 1 min with a final extension of 5 min at 72°C.
All reactions were performed using Platinum Taq Super-
Mix (Invitrogen).
Real-time quantitative PCR
RNA was isolated from hepatocyte-cancer cell co-cul-
tures with the PureYield RNA Midiprep System (Pro-
mega, Madison, WI). cDNA was obtained with High
Capacity cDNA RT Kit (Applied BioSystems, Foster City,
CA). The human-specific TaqMan Gene Expression
Assay Hs00170423_A1 CDHI probe was obtained from
Applied Biosystems (Foster City, CA). Amplification and
analysis in quadruplicate was run in an Applied Biosys-
tems 7500 Real-Time PCR System. Relative values were
normalized by using GAPDH levels as a reference using
TaqMan Pre-Developed Human GAPDH Assay Reagent
by Applied Biosystems.
Immunoblotting, Immunofluorescence, and Flow 
Cytometry
Cell lysate proteins were resolved on 7.5% SDS-PAGE and
and transferred to PVDF membranes. After blocking,
membranes were incubated with primary antibodies
against E-cdherin (Santa Cruz), pan cytokeratin (abcam),
smooth muscle actin (Cal Biochem), fibronectin (Rock-
land Inc), GAPDH (Sigma) and actin (Sigma), followed by
incubation with peroxidase-conjugated secondary anti-
bodies and chemiluminescence detection.
For flow cytometry, co-cultures were non-ezymatically
dissociated from the culture plates and vortexed into a
single-cell suspension. The cells were fixed in 2% Para-
formaldehyde for 30 minutes, permeabilized with 1% Tri-
ton for 3 minutes, and incubated with a PE-conjugated E-
cadherin antibody (67A4) for 30 minutes. The mixed
hepatocyte-cancer cell suspension was gated as to
exclude hepatocytes using the appropriate SSC/FSC
parameters. Data were collected on at least 106 cells in the
appropriate SSC/FSC region.
Immunofluorescence was performed by overnight pri-
mary antibody incubation with E-cadherin (Santa Cruz),
DNMT1 (Santa Cruz), DsRed (Santa Cruz), Alexa 488-
phalloidin (Molecular Probes), cytokeratin-18 (abcam) or
vimentin (abcam) followed by incubation with the appro-
priate fluorophore-labeled secondary antibody. Visualiza-
tion was performed on an Olympus Fluoview 1000
confocal microscope (Olympus, Center Valley, PA).
Primary explants
Polyclonal primary human tumor explants were obtained
and cultured as previously reported [26]. Immunofluo-
rescence labeling was performed as above.
Statistical Analysis
All quantitative data are presented as mean ± sd obtained
from independent experiments. p-value significance was
determined using a two-tailed unpaired Student t-test,
and set at 0.05 as a minimum. All images were represen-
tative of at least three independent observations.
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